Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 571,860 |
|
|||||
| News | (3) | ||||||
| Day High | 13.66 | Low High |
|||||
| Day Low | 13.31 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Evolus Inc | EOLS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.08 | 0.60% | 13.47 | 18:33:18 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 13.31 | 13.31 | 13.66 | 13.42 | 13.39 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 7,545 | 571,860 | $ 13.49 | $ 7,713,221 | - | 7.07 - 15.4325 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:33:18 | formt | 200 | $ 13.47 | USD |
Evolus Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 777.6M | 57.94M | - | 202.09M | -61.69M | -1.06 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Evolus News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EOLS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 11.68 | 13.66 | 11.58 | 12.92 | 802,289 | 1.79 | 15.33% |
| 1 Month | 13.36 | 13.66 | 11.07 | 12.27 | 536,159 | 0.11 | 0.82% |
| 3 Months | 13.33 | 15.4325 | 11.07 | 13.46 | 596,687 | 0.14 | 1.05% |
| 6 Months | 8.00 | 15.4325 | 7.74 | 11.71 | 664,894 | 5.47 | 68.38% |
| 1 Year | 8.53 | 15.4325 | 7.07 | 10.31 | 633,838 | 4.94 | 57.91% |
| 3 Years | 8.70 | 15.4325 | 5.061 | 9.80 | 542,041 | 4.77 | 54.83% |
| 5 Years | 25.00 | 25.30 | 2.85 | 9.59 | 650,710 | -11.53 | -46.12% |
Evolus Description
| Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton or kDa, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. |
